About ABBV-744 as a potential therapeutic option for aggressive cancers
These side effects ended up notably milder when compared to an inhibitor of the two bromodomains. An in depth molecular Assessment also unveiled that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes. ― Stephen Taylor88 These preclinical studies offer paradigms for foreseeable future clinical trials in AM